Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Prudence Ive

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
AIDS (London, England)|March 17, 2018
Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan AfricaStefanie Kroeze, Pascale Ondoa, Cissy M Kityo, et al.
Southern African Journal of HIV Medicine|March 24, 2020
Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 updateNelesh P Govender, Graeme Meintjes, Phetho Mangena, et al.
The New England Journal of Medicine|October 21, 2011
Timing of antiretroviral therapy for HIV-1 infection and tuberculosisDiane V Havlir, Michelle A Kendall, Prudence Ive, et al.
Journal of Neurovirology|May 27, 2010
NeuroAIDS in AfricaKevin Robertson, Jeff Liner, James Hakim, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Lancet (London, England)|March 22, 2015
Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosisRodney Dawson, Andreas H Diacon, Daniel Everitt, et al.
AIDS (London, England)|March 17, 2018
Suboptimal immune recovery during antiretroviral therapy with sustained HIV suppression in sub-Saharan AfricaStefanie Kroeze, Pascale Ondoa, Cissy M Kityo, et al.
Southern African Journal of HIV Medicine|March 24, 2020
Southern African HIV Clinicians Society guideline for the prevention, diagnosis and management of cryptococcal disease among HIV-infected persons: 2019 updateNelesh P Govender, Graeme Meintjes, Phetho Mangena, et al.
The New England Journal of Medicine|October 21, 2011
Timing of antiretroviral therapy for HIV-1 infection and tuberculosisDiane V Havlir, Michelle A Kendall, Prudence Ive, et al.
Journal of Neurovirology|May 27, 2010
NeuroAIDS in AfricaKevin Robertson, Jeff Liner, James Hakim, et al.
Pageof 5